To determine if the out-of-field ORR is improved with the addition of radiation therapy to
anti-PD-1 for patients with MSI-H/dMMR metastatic solid tumors. Determine the rates of
in-field tumor control, disease control (stable disease, partial response, complete
response), durability of disease response, progression-free survival, overall survival, and
to assess quality of life and toxicity. Determine the chronology and profile of the
radiation-associated immune response.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Cancer League of Colorado, Inc National Cancer Institute (NCI)